{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:21Z","timestamp":1790767341747,"version":"4.1.0"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"1","funder":[{"name":"European Respiratory Society \/ Canadian Thoracic Society","award":["LTRF 2015-4780"],"award-info":[{"award-number":["LTRF 2015-4780"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2017,5,23]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.<\/jats:p><jats:p>21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1\u201381)\u2005months).<\/jats:p><jats:p>Median age was 52\u2005years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42\u2005(8\u201374)\u2005months before PAH diagnosis. No bone morphogenic protein receptor-2 (<jats:italic>BMPR2<\/jats:italic>) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New\u00a0York Heart Association functional class improved from 76% in class III\/IV to 90% in class I\/II (p&lt;0.01). Median (range) 6-min walk distance improved from 306\u2005(0\u2013660) to 430\u2005(165\u2013635)\u2005m (p&lt;0.01). Median (range) mean pulmonary arterial pressure improved from 45\u2005(30\u201370) to 26\u2005(17\u201350)\u2005mmHg (p&lt;0.01) and pulmonary vascular resistance from 6.1\u2005(3.2\u201327.3) to 2.6\u2005(1.2\u20135.9)\u2005Wood units (p&lt;0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.<\/jats:p><jats:p>Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.<\/jats:p>","DOI":"10.1183\/13993003.00217-2017","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:10:16Z","timestamp":1501200616000},"page":"1700217","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":124,"title":["Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study"],"prefix":"10.1183","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-4575","authenticated-orcid":false,"given":"Jason","family":"Weatherald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Canuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Bouvaist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-4452","authenticated-orcid":false,"given":"Christophe","family":"Guignabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"2024101904164616000_50.1.1700217.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024101904164616000_50.1.1700217.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"2024101904164616000_50.1.1700217.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0862"},{"key":"2024101904164616000_50.1.1700217.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"2024101904164616000_50.1.1700217.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"2024101904164616000_50.1.1700217.6","unstructured":"US Food and Drug Administration. Sprycel (dasatinib) prescribing and labeling information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf Date last accessed January 10, 2017."},{"key":"2024101904164616000_50.1.1700217.7","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801896103"},{"key":"2024101904164616000_50.1.1700217.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"2024101904164616000_50.1.1700217.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01410-2016"},{"key":"2024101904164616000_50.1.1700217.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01004-2016"},{"key":"2024101904164616000_50.1.1700217.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01110-2015"},{"key":"2024101904164616000_50.1.1700217.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"2024101904164616000_50.1.1700217.13","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1085"},{"key":"2024101904164616000_50.1.1700217.14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24174"},{"key":"2024101904164616000_50.1.1700217.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00021915"},{"key":"2024101904164616000_50.1.1700217.16","first-page":"999","article-title":"Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia","volume":"57","author":"Morishita","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"2024101904164616000_50.1.1700217.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"2024101904164616000_50.1.1700217.18","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"2024101904164616000_50.1.1700217.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035913"},{"key":"2024101904164616000_50.1.1700217.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249"},{"key":"2024101904164616000_50.1.1700217.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057914"},{"key":"2024101904164616000_50.1.1700217.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01376-2015"},{"key":"2024101904164616000_50.1.1700217.23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MCP.0000000000000307","article-title":"Interferon-induced pulmonary hypertension: an update","volume":"22","author":"Savale","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2024101904164616000_50.1.1700217.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-1037OC"},{"key":"2024101904164616000_50.1.1700217.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0905OC"},{"key":"2024101904164616000_50.1.1700217.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2024101904164616000_50.1.1700217.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2024101904164616000_50.1.1700217.28","first-page":"89","article-title":"Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib","volume":"3","author":"Swords","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"2024101904164616000_50.1.1700217.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-113969"},{"key":"2024101904164616000_50.1.1700217.30","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2024101904164616000_50.1.1700217.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"2024101904164616000_50.1.1700217.32","first-page":"A2797","article-title":"Dasatinib causes pulmonary endothelial damage and increases endothelial permeability","volume":"193","author":"Jutant","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101904164616000_50.1.1700217.33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"2024101904164616000_50.1.1700217.34","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12022"},{"key":"2024101904164616000_50.1.1700217.35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring","volume":"35","author":"Josephs","year":"2013","journal-title":"Ther Drug Monit"},{"key":"2024101904164616000_50.1.1700217.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00211811"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00217-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:42:51Z","timestamp":1740379371000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00217-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,27]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1183\/13993003.00217-2017"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00217-2017","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}